Thomas M Habermann
Thomas M Habermann is an expert in Hematology at Mayo Clinic (United States, Rochester) (United States). As of October 2026, ScienceLeadR ranks Thomas M Habermann in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Thomas M Habermann has authored 923 publications, the most recent in 2026, and is an investigator in 17 clinical trials. SLR score: 2,968 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1992 - 2026
Number : 923
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study. PMID 42897159 — cells, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes, receptors, antigen, t-cell | Blood Cancer J | 2026 | 0 |
| Impact of a Virtual Multidisciplinary Lymphoma Tumor Board on Clinical Decision-Making. PMID 42894807 — clinical decision-making, lymphoma, neoplasms, pathology, decision making, radiology | Mayo Clin Proc Innov Qual Outcomes | 2026 | 0 |
| The Baseline Molecular Profile of Late Relapse: Identifying Drivers of Delayed Recurrence in DLBCL. PMID 42861738 — genomics, gene expression profiling, medical oncology, b-lymphocytes | Hematol Oncol | 2026 | 0 |
| EBV-Positive Sinonasal Plasma Cell Neoplasms: A Case Series With Favorable Outcomes in Elderly Males. PMID 42824828 — neoplasms, plasma cell, cells, lymphoma, plasma cells, neoplasms, plasmacytoma, plasmablastic lymphoma, aged, herpesvirus 4, human, plasma | EJHaem | 2026 | 0 |
| Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis. PMID 42787875 — cells, lymphoma, neoplasms, drug therapy, chemoradiotherapy, lymphoma, mantle-cell, therapeutics, chemotherapy | Blood Neoplasia | 2026 | 0 |
Clinical Studies 17
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map